EXTRACORPOREAL PHOTOPHERESIS (ECP) FOR TREATEMENT OF ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE

AN ITALIAN MULTICENTRIC RETROSPECTIVE ANALYSIS ON 94 PATIENTS ON BEHALF OF THE GRUPPO ITALIANO TRAPIANTO DI MIDOLLO OSSEO (GITMO)

M. Malagola, Valeria Cancelli, Cristina Skert, Pierino Ferremi Leali, Emilio Ferrari, A. Tiburzi, Maria Luisa Sala, I. Donnini, Patrizia Chiusolo, Alberto Muffetti, Marta Lisa Battista, Alessandro Turra, Federica Cattina, Benedetta Rambaldi, Francesca Schieppati, Nicola Polverelli, Simona Bernardi, Simone Perucca, M. Marini, Daniele Laszlo & 7 others Chiara Savignano, F. Patriarca, Paolo Corradini, Nicola Piccirillo, Simona Sica, Alberto Bosi, Domenico Russo

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Extracorporeal photopheresis (ECP) is considered a valid second-line treatment for acute and chronic graft versus host disease (GVHD). METHODS: Ninety-four patients with aGVHD (n=45) and cGVHD (n=49), retrospectively recruited in 6 Italian Centers, were submitted to ECP for second-line treatment. At the time of ECP, 22 (49%) and 23 (51%) out of 45 patients with aGHVD were non responsive (NR) and in partial remission (PR) after steroids, respectively, and all the 49 patients with cGVHD were steroid refractory. RESULTS: Forty-one out of 45 (91%) patients with aGVHD achieved complete remission (CR) after ECP. Fifteen out of 45 (33%) patients developed cGVHD. The CR rate in patients who started ECP being NR and in PR after steroid was 86% and 96%, respectively. After a median follow up of 20 months (range 2–72), 15/45 patients (33%) developed cGHVD and 16/45 patients (35%) died, in 3 cases for aGVHD. A trend for a better survival was seen among patients who started ECP in PR after steroid (80% vs 50% at 2 years; p=0,07). Overall, 22/49 (45%) and 17/49 (35%) patients with steroid refractory cGHVD achieved CR and PR after ECP, respectively. After a median follow up of 27 months, 44/49 patients (90%) are alive, 21 of whom (48%) on steroid. CONCLUSIONS: ECP is confirmed as an effective second-line treatment in both acute and chronic GVHD, as it can induce a response in more than 80% of the patients and a long term survival in at least 50% of the cases.

Original languageEnglish
JournalTransplantation
DOIs
Publication statusAccepted/In press - Sep 8 2016

Fingerprint

Photopheresis
Graft vs Host Disease
Steroids
Survival

ASJC Scopus subject areas

  • Medicine(all)
  • Transplantation

Cite this

EXTRACORPOREAL PHOTOPHERESIS (ECP) FOR TREATEMENT OF ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE : AN ITALIAN MULTICENTRIC RETROSPECTIVE ANALYSIS ON 94 PATIENTS ON BEHALF OF THE GRUPPO ITALIANO TRAPIANTO DI MIDOLLO OSSEO (GITMO). / Malagola, M.; Cancelli, Valeria; Skert, Cristina; Leali, Pierino Ferremi; Ferrari, Emilio; Tiburzi, A.; Sala, Maria Luisa; Donnini, I.; Chiusolo, Patrizia; Muffetti, Alberto; Battista, Marta Lisa; Turra, Alessandro; Cattina, Federica; Rambaldi, Benedetta; Schieppati, Francesca; Polverelli, Nicola; Bernardi, Simona; Perucca, Simone; Marini, M.; Laszlo, Daniele; Savignano, Chiara; Patriarca, F.; Corradini, Paolo; Piccirillo, Nicola; Sica, Simona; Bosi, Alberto; Russo, Domenico.

In: Transplantation, 08.09.2016.

Research output: Contribution to journalArticle

Malagola, M, Cancelli, V, Skert, C, Leali, PF, Ferrari, E, Tiburzi, A, Sala, ML, Donnini, I, Chiusolo, P, Muffetti, A, Battista, ML, Turra, A, Cattina, F, Rambaldi, B, Schieppati, F, Polverelli, N, Bernardi, S, Perucca, S, Marini, M, Laszlo, D, Savignano, C, Patriarca, F, Corradini, P, Piccirillo, N, Sica, S, Bosi, A & Russo, D 2016, 'EXTRACORPOREAL PHOTOPHERESIS (ECP) FOR TREATEMENT OF ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE: AN ITALIAN MULTICENTRIC RETROSPECTIVE ANALYSIS ON 94 PATIENTS ON BEHALF OF THE GRUPPO ITALIANO TRAPIANTO DI MIDOLLO OSSEO (GITMO)', Transplantation. https://doi.org/10.1097/TP.0000000000001466
Malagola, M. ; Cancelli, Valeria ; Skert, Cristina ; Leali, Pierino Ferremi ; Ferrari, Emilio ; Tiburzi, A. ; Sala, Maria Luisa ; Donnini, I. ; Chiusolo, Patrizia ; Muffetti, Alberto ; Battista, Marta Lisa ; Turra, Alessandro ; Cattina, Federica ; Rambaldi, Benedetta ; Schieppati, Francesca ; Polverelli, Nicola ; Bernardi, Simona ; Perucca, Simone ; Marini, M. ; Laszlo, Daniele ; Savignano, Chiara ; Patriarca, F. ; Corradini, Paolo ; Piccirillo, Nicola ; Sica, Simona ; Bosi, Alberto ; Russo, Domenico. / EXTRACORPOREAL PHOTOPHERESIS (ECP) FOR TREATEMENT OF ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE : AN ITALIAN MULTICENTRIC RETROSPECTIVE ANALYSIS ON 94 PATIENTS ON BEHALF OF THE GRUPPO ITALIANO TRAPIANTO DI MIDOLLO OSSEO (GITMO). In: Transplantation. 2016.
@article{5d015214cd8d47dea320b595c190616c,
title = "EXTRACORPOREAL PHOTOPHERESIS (ECP) FOR TREATEMENT OF ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE: AN ITALIAN MULTICENTRIC RETROSPECTIVE ANALYSIS ON 94 PATIENTS ON BEHALF OF THE GRUPPO ITALIANO TRAPIANTO DI MIDOLLO OSSEO (GITMO)",
abstract = "BACKGROUND: Extracorporeal photopheresis (ECP) is considered a valid second-line treatment for acute and chronic graft versus host disease (GVHD). METHODS: Ninety-four patients with aGVHD (n=45) and cGVHD (n=49), retrospectively recruited in 6 Italian Centers, were submitted to ECP for second-line treatment. At the time of ECP, 22 (49{\%}) and 23 (51{\%}) out of 45 patients with aGHVD were non responsive (NR) and in partial remission (PR) after steroids, respectively, and all the 49 patients with cGVHD were steroid refractory. RESULTS: Forty-one out of 45 (91{\%}) patients with aGVHD achieved complete remission (CR) after ECP. Fifteen out of 45 (33{\%}) patients developed cGVHD. The CR rate in patients who started ECP being NR and in PR after steroid was 86{\%} and 96{\%}, respectively. After a median follow up of 20 months (range 2–72), 15/45 patients (33{\%}) developed cGHVD and 16/45 patients (35{\%}) died, in 3 cases for aGVHD. A trend for a better survival was seen among patients who started ECP in PR after steroid (80{\%} vs 50{\%} at 2 years; p=0,07). Overall, 22/49 (45{\%}) and 17/49 (35{\%}) patients with steroid refractory cGHVD achieved CR and PR after ECP, respectively. After a median follow up of 27 months, 44/49 patients (90{\%}) are alive, 21 of whom (48{\%}) on steroid. CONCLUSIONS: ECP is confirmed as an effective second-line treatment in both acute and chronic GVHD, as it can induce a response in more than 80{\%} of the patients and a long term survival in at least 50{\%} of the cases.",
author = "M. Malagola and Valeria Cancelli and Cristina Skert and Leali, {Pierino Ferremi} and Emilio Ferrari and A. Tiburzi and Sala, {Maria Luisa} and I. Donnini and Patrizia Chiusolo and Alberto Muffetti and Battista, {Marta Lisa} and Alessandro Turra and Federica Cattina and Benedetta Rambaldi and Francesca Schieppati and Nicola Polverelli and Simona Bernardi and Simone Perucca and M. Marini and Daniele Laszlo and Chiara Savignano and F. Patriarca and Paolo Corradini and Nicola Piccirillo and Simona Sica and Alberto Bosi and Domenico Russo",
year = "2016",
month = "9",
day = "8",
doi = "10.1097/TP.0000000000001466",
language = "English",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - EXTRACORPOREAL PHOTOPHERESIS (ECP) FOR TREATEMENT OF ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE

T2 - AN ITALIAN MULTICENTRIC RETROSPECTIVE ANALYSIS ON 94 PATIENTS ON BEHALF OF THE GRUPPO ITALIANO TRAPIANTO DI MIDOLLO OSSEO (GITMO)

AU - Malagola, M.

AU - Cancelli, Valeria

AU - Skert, Cristina

AU - Leali, Pierino Ferremi

AU - Ferrari, Emilio

AU - Tiburzi, A.

AU - Sala, Maria Luisa

AU - Donnini, I.

AU - Chiusolo, Patrizia

AU - Muffetti, Alberto

AU - Battista, Marta Lisa

AU - Turra, Alessandro

AU - Cattina, Federica

AU - Rambaldi, Benedetta

AU - Schieppati, Francesca

AU - Polverelli, Nicola

AU - Bernardi, Simona

AU - Perucca, Simone

AU - Marini, M.

AU - Laszlo, Daniele

AU - Savignano, Chiara

AU - Patriarca, F.

AU - Corradini, Paolo

AU - Piccirillo, Nicola

AU - Sica, Simona

AU - Bosi, Alberto

AU - Russo, Domenico

PY - 2016/9/8

Y1 - 2016/9/8

N2 - BACKGROUND: Extracorporeal photopheresis (ECP) is considered a valid second-line treatment for acute and chronic graft versus host disease (GVHD). METHODS: Ninety-four patients with aGVHD (n=45) and cGVHD (n=49), retrospectively recruited in 6 Italian Centers, were submitted to ECP for second-line treatment. At the time of ECP, 22 (49%) and 23 (51%) out of 45 patients with aGHVD were non responsive (NR) and in partial remission (PR) after steroids, respectively, and all the 49 patients with cGVHD were steroid refractory. RESULTS: Forty-one out of 45 (91%) patients with aGVHD achieved complete remission (CR) after ECP. Fifteen out of 45 (33%) patients developed cGVHD. The CR rate in patients who started ECP being NR and in PR after steroid was 86% and 96%, respectively. After a median follow up of 20 months (range 2–72), 15/45 patients (33%) developed cGHVD and 16/45 patients (35%) died, in 3 cases for aGVHD. A trend for a better survival was seen among patients who started ECP in PR after steroid (80% vs 50% at 2 years; p=0,07). Overall, 22/49 (45%) and 17/49 (35%) patients with steroid refractory cGHVD achieved CR and PR after ECP, respectively. After a median follow up of 27 months, 44/49 patients (90%) are alive, 21 of whom (48%) on steroid. CONCLUSIONS: ECP is confirmed as an effective second-line treatment in both acute and chronic GVHD, as it can induce a response in more than 80% of the patients and a long term survival in at least 50% of the cases.

AB - BACKGROUND: Extracorporeal photopheresis (ECP) is considered a valid second-line treatment for acute and chronic graft versus host disease (GVHD). METHODS: Ninety-four patients with aGVHD (n=45) and cGVHD (n=49), retrospectively recruited in 6 Italian Centers, were submitted to ECP for second-line treatment. At the time of ECP, 22 (49%) and 23 (51%) out of 45 patients with aGHVD were non responsive (NR) and in partial remission (PR) after steroids, respectively, and all the 49 patients with cGVHD were steroid refractory. RESULTS: Forty-one out of 45 (91%) patients with aGVHD achieved complete remission (CR) after ECP. Fifteen out of 45 (33%) patients developed cGVHD. The CR rate in patients who started ECP being NR and in PR after steroid was 86% and 96%, respectively. After a median follow up of 20 months (range 2–72), 15/45 patients (33%) developed cGHVD and 16/45 patients (35%) died, in 3 cases for aGVHD. A trend for a better survival was seen among patients who started ECP in PR after steroid (80% vs 50% at 2 years; p=0,07). Overall, 22/49 (45%) and 17/49 (35%) patients with steroid refractory cGHVD achieved CR and PR after ECP, respectively. After a median follow up of 27 months, 44/49 patients (90%) are alive, 21 of whom (48%) on steroid. CONCLUSIONS: ECP is confirmed as an effective second-line treatment in both acute and chronic GVHD, as it can induce a response in more than 80% of the patients and a long term survival in at least 50% of the cases.

UR - http://www.scopus.com/inward/record.url?scp=84986182464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986182464&partnerID=8YFLogxK

U2 - 10.1097/TP.0000000000001466

DO - 10.1097/TP.0000000000001466

M3 - Article

JO - Transplantation

JF - Transplantation

SN - 0041-1337

ER -